| 1 |
Czaja AJ. Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. Dig Dis Sci 2022;67:4979-5005. [PMID: 35147819 DOI: 10.1007/s10620-021-07378-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 2 |
Radu AF, Bungau SG, Negru PA, Marcu MF, Andronie-Cioara FL. In-depth bibliometric analysis and current scientific mapping research in the context of rheumatoid arthritis pharmacotherapy. Biomed Pharmacother 2022;154:113614. [PMID: 36058148 DOI: 10.1016/j.biopha.2022.113614] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Schreiber S, Ben-horin S, Alten R, Westhovens R, Peyrin-biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim D, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022;39:2342-2364. [DOI: 10.1007/s12325-021-01990-6] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 4 |
Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022;39:2342-64. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 5 |
Wang F, Liu G, Xiang L, Yuan J, Tao Y, Zhang L, Zhang A, Chang X. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 in rheumatoid arthritis: Longitudinal change after treatment and correlation with treatment efficacy of tumor necrosis factor inhibitors. J Clin Lab Anal 2022;:e24449. [PMID: 35500150 DOI: 10.1002/jcla.24449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Elahi R, Karami P, Heidary AH, Esmaeilzadeh A. An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19). Int Immunopharmacol 2022;105:108536. [PMID: 35074571 DOI: 10.1016/j.intimp.2022.108536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 7 |
Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells 2021;10:2857. [PMID: 34831081 DOI: 10.3390/cells10112857] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 8 |
Roszkowski L, Ciechomska M. Tuning Monocytes and Macrophages for Personalized Therapy and Diagnostic Challenge in Rheumatoid Arthritis. Cells 2021;10:1860. [PMID: 34440629 DOI: 10.3390/cells10081860] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
